Medtronic has launched its Adaptive Deep Brain Stimulation (aDBS) system in India, the company said, offering a device that automatically adjusts stimulation in response to brain signals and patient activity to manage symptoms of Parkinson’s disease.

The system uses Medtronic’s US FDA‑approved BrainSense sensing technology to read neural signals and adapt therapy in real time. The company said aDBS is intended to deliver more consistent symptom control than standard DBS, which typically requires manual adjustments by clinicians, patients or caregivers.

Medtronic said the device can respond to changes in a patient’s condition or medication needs, which the company expects will reduce side effects and help extend the implanted device’s battery life.

“We are extremely proud to introduce this advanced technology in India, where Parkinson’s disease is an increasingly significant healthcare concern,” Prateek Tiwari, Senior Director, Neuroscience & Specialty therapies, Medtronic India, said in a company statement. “This milestone … strengthens our leadership in bringing cutting‑edge healthcare technologies to India to ultimately improve patients’ quality of life.”

Medtronic outlined the typical DBS care pathway: patients first consult a Movement Disorder Specialist, often a neurologist, for assessment and referral to a comprehensive DBS clinic or neurosurgery board. A Functional Neurosurgeon performs implantation and programming if the patient is deemed suitable.

The company noted India accounts for about 10% of the global Parkinson’s disease burden and said the country is expected to see a substantial rise in cases within the next five years.

Photo credit: media.fortuneindia.com

Tags: adaptive deep brain stimulation, Parkinson's disease, Medtronic, BrainSense, neuromodulation

Topics: Neuromodulation, Deep brain stimulation, Neuroprosthetics & neural implants